Lung Cancer Europe (LuCE) proudly took an active role in the third annual meeting of the I3LUNG consortium, held this June in Corfu, Greece. As part of the Horizon 2020 EU-funded initiative, I3LUNG is advancing an ambitious goal: to use artificial intelligence (AI) to personalize treatment decisions for lung cancer patients—improving accuracy, efficiency, and putting the patient firmly at the center of care.

During the event, our EU Project Manager, Anniina Hentinen, presented key findings from a large-scale survey led by LuCE, exploring patient and caregiver perceptions of AI in cancer treatment. With input from over 200 participants across Europe, the results reveal both enthusiasm and important concerns:

• Over 60% of patients viewed AI as more beneficial than traditional decision-making methods
• Nearly 80% were willing to share personal data to support improved treatment outcomes
• Top advantages identified included increased accuracy, faster clinical decisions, and more personalized care pathways

At the same time, the survey shed light on areas that must not be overlooked:

• Concerns about the loss of human connection, reduced face-to-face interaction, and limited transparency in how AI makes decisions
• A strong need for trust-building, patient education, and meaningful involvement in the development and application of AI tools

These insights are already shaping the future of the I3LUNG project. The consortium’s patient co-decision tool—now in prototype development—is designed to empower patients with accessible information while ensuring that clinicians maintain oversight. By integrating patient-reported outcomes and quality-of-life measures, the tool aims to improve not only the precision of care, but its compassion as well.

The meeting also marked important milestones beyond our presentation. The launch of the European Society of Artificial Intelligence in Cancer (ESAC), the creation of the first Summer School on AI in Oncology, and growing connections with other EU-funded initiatives reflect I3LUNG’s expanding impact and commitment to collaboration.

As always, LuCE remains dedicated to ensuring that the patient voice guides every step of innovation. We firmly believe that technology should enhance—not replace—the human side of cancer care. Through initiatives like I3LUNG, we are working to shape a future where AI supports better outcomes, deeper understanding, and more humane treatment for all those affected by lung cancer.

For more about the I3LUNG project, visit www.i3lung.eu.